Business Description
Supernus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US8684591089
Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.14 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.46 | |||||
| Interest Coverage | 5.55 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.92 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.1 | |||||
| 3-Year EBITDA Growth Rate | -25.5 | |||||
| 3-Year EPS without NRI Growth Rate | -50.7 | |||||
| 3-Year FCF Growth Rate | -7.4 | |||||
| 3-Year Book Growth Rate | 6.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.84 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.8 | |||||
| 9-Day RSI | 31.52 | |||||
| 14-Day RSI | 39.12 | |||||
| 6-1 Month Momentum % | 24.59 | |||||
| 12-1 Month Momentum % | -6.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | |||||
| Quick Ratio | 1.43 | |||||
| Cash Ratio | 0.88 | |||||
| Days Inventory | 378.28 | |||||
| Days Sales Outstanding | 87.9 | |||||
| Days Payable | 27.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | 17.12 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.21 | |||||
| Operating Margin % | 2.21 | |||||
| Net Margin % | 0.22 | |||||
| FCF Margin % | 18.24 | |||||
| ROE % | 0.14 | |||||
| ROA % | 0.09 | |||||
| ROIC % | 0.57 | |||||
| ROC (Joel Greenblatt) % | 5.08 | |||||
| ROCE % | 0.51 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 110.64 | |||||
| Shiller PE Ratio | 21.75 | |||||
| Price-to-Owner-Earnings | 32.81 | |||||
| PS Ratio | 2.74 | |||||
| PB Ratio | 1.75 | |||||
| Price-to-Tangible-Book | 7.75 | |||||
| Price-to-Free-Cash-Flow | 15.48 | |||||
| Price-to-Operating-Cash-Flow | 15.4 | |||||
| EV-to-EBIT | 265.04 | |||||
| EV-to-EBITDA | 15.26 | |||||
| EV-to-Revenue | 2.26 | |||||
| EV-to-FCF | 12.64 | |||||
| Price-to-Projected-FCF | 0.83 | |||||
| Price-to-Median-PS-Value | 0.58 | |||||
| Price-to-Graham-Number | 6.13 | |||||
| Price-to-Net-Current-Asset-Value | 11.6 | |||||
| Earnings Yield (Greenblatt) % | 0.38 | |||||
| FCF Yield % | 6.96 | |||||
| Forward Rate of Return (Yacktman) % | -4.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Supernus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 563.603 | ||
| EPS (TTM) (€) | -0.003 | ||
| Beta | 0.69 | ||
| Volatility % | 31.1 | ||
| 14-Day RSI | 39.12 | ||
| 14-Day ATR (€) | 0.613036 | ||
| 20-Day SMA (€) | 30.24 | ||
| 12-1 Month Momentum % | -6.75 | ||
| 52-Week Range (€) | 21.4 - 34 | ||
| Shares Outstanding (Mil) | 54.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Supernus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Supernus Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Supernus Pharmaceuticals Inc Frequently Asked Questions
What is Supernus Pharmaceuticals Inc(FRA:S49)'s stock price today?
The current price of FRA:S49 is €27.60. The 52 week high of FRA:S49 is €34.00 and 52 week low is €21.40.
When is next earnings date of Supernus Pharmaceuticals Inc(FRA:S49)?
The next earnings date of Supernus Pharmaceuticals Inc(FRA:S49) is 2024-05-09 Est..
Does Supernus Pharmaceuticals Inc(FRA:S49) pay dividends? If so, how much?
Supernus Pharmaceuticals Inc(FRA:S49) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers